↑ 薬物リストへ　← 戻る

Oprelvekin, interleukin 11, il-11    (DrugBank: Oprelvekin, IL-11, Interleukin 11)

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
288自己免疫性後天性凝固因子欠乏症［自己免疫性出血病XIII (~2017.3)］3

288. 自己免疫性後天性凝固因子欠乏症［自己免疫性出血病XIII (~2017.3)］　［臨床試験数：189，薬物数：219（DrugBank：29），標的遺伝子数：18，標的パスウェイ数：26］
Searched query = "Autoimmune acquired coagulation factor deficiency", "Coagulation factor deficiency", "Factor XIII deficiency", "Factor VIII deficiency", "Acquired hemophilia A", "von Willebrand Disease", "Factor V deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 189 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00994929
(ClinicalTrials.gov)		January 201012/10/2009Efficacy and Safety of IL-11 in DDAVP UnresponsivePhase II Biologic Effects Study of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Moderate or Mild Hemophilia A, or Von Willebrand Disease Unable to Use DDAVPHemophilia A;Von Willebrand DiseaseBiological: Neumega (Oprelvekin, Interleukin 11, IL-11)University of PittsburghNULLCompleted18 YearsN/AAll9Phase 2United States
2NCT00524225
(ClinicalTrials.gov)		February 200831/8/2007IL-11 in Adults With Von Willebrand Disease Undergoing SurgeryPhase II Clinical Efficacy Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Subjects With Type 1 Von Willebrand Disease Undergoing SurgeryVon Willebrand DiseaseDrug: Neumega (Oprelvekin, Interleukin 11, IL-11)Margaret RagniUniversity of North Carolina;Wyeth is now a wholly owned subsidiary of PfizerTerminated18 YearsN/AAll3Phase 2United States
3NCT00524342
(ClinicalTrials.gov)		January 200831/8/2007IL-11 in Women With Von Willebrand Disease and Refractory MenorrhagiaPhase II Clinical Efficacy Trial of Recombinant Interleukin-11 (rhIL-11, Neumega) in Women With Type 1 Von Willebrand Disease and Refractory MenorrhagiaVon Willebrand DiseaseDrug: Oprelvekin, Interleukin 11, IL-11Margaret RagniUniversity of North Carolina;Wyeth is now a wholly owned subsidiary of PfizerCompleted18 Years45 YearsFemale7Phase 2United States